Here, we evaluate the genomic landscape of NF1 alterations in IDH-wildtype glioblastoma, validate an immunohistochemical biomarker for NF1 loss, and identify other immunohistochemical, genomic, and clinical correlates of NF1 immunostaining. Here, IDH1 is linked to glioblastoma.